Omega-3 Fatty Acids (EPA/DHA)

EPA and DHA are long-chain n-3 polyunsaturated fatty acids that competitively inhibit arachidonic acid metabolism, incorporate into cell membrane phospholipids, and serve as precursors to anti-inflammatory eicosanoids, resolvins, protectins, and maresins. In a meta-analysis of over 120,000 participants across 13 large randomized trials, combined EPA+DHA supplementation at ≥1 g/day reduced major cardiovascular events by approximately 9% and cardiovascular mortality by 13%, with the high-dose icosapentaenoic acid ethyl ester trial REDUCE-IT demonstrating a 25% reduction in major adverse cardiovascular events at 4 g/day EPA.

Origin & History

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) originate biosynthetically in marine microalgae and phytoplankton, then bioaccumulate through the marine food chain into oily cold-water fish species such as sardines, anchovies, mackerel, herring, and salmon. Commercial fish oil is extracted primarily from small pelagic species harvested in the South Pacific, North Atlantic, and Norwegian Sea, where cold, nutrient-rich waters support dense microalgal populations. The oil is refined through degumming, neutralization, bleaching, and deodorization steps to produce food-grade concentrates, with pharmaceutical-grade ethyl ester or re-esterified triglyceride forms achieving EPA+DHA concentrations exceeding 80–90% by weight.

Historical & Cultural Context

The medicinal use of fish liver oils, particularly cod liver oil (Gadus morhua), dates to at least the 18th century in Northern Europe, where Norwegian and British physicians prescribed it for rickets, rheumatism, and wound healing, with the Edinburgh Pharmacopoeia formally listing oleum jecoris aselli (cod liver oil) in 1765. Coastal and Arctic indigenous populations — including the Inuit, Yup'ik, and Scandinavian fishing communities — consumed large quantities of oily fish, seal blubber, and whale fat as dietary staples for centuries, an empirical practice that epidemiologists later connected to their remarkably low rates of cardiovascular disease, a relationship first formally described by Bang and Dyerberg in Greenlandic Inuit studies published in 1971–1980. The biochemical isolation and characterization of EPA and DHA as distinct bioactive entities emerged from the 1970s–1980s research of Ralph Holman and colleagues, and the development of commercial fish oil concentrates as pharmaceutical-grade supplements accelerated through the 1990s following the landmark GISSI-Prevenzione trial. Traditional Ayurvedic and East Asian medical texts reference fish as 'brain-nourishing' and 'cold-dampness-dispelling' foods, though the attribution of specific omega-3 fatty acids as the active principle is entirely a product of 20th-century analytical biochemistry.

Health Benefits

- **Cardiovascular Risk Reduction**: EPA and DHA lower serum triglycerides by 20–50% at doses of 2–4 g/day by suppressing hepatic VLDL synthesis and upregulating fatty acid beta-oxidation; meta-analyses confirm significant reductions in cardiovascular mortality and non-fatal myocardial infarction across high-risk populations.
- **Systemic Anti-Inflammatory Action**: Both fatty acids displace arachidonic acid from membrane phospholipids, reducing production of pro-inflammatory prostaglandins, thromboxanes, and leukotrienes (series-2 and series-4), while EPA and DHA serve as direct substrates for synthesis of specialized pro-resolving mediators (SPMs) including resolvins E1/E2 and protectins D1 that actively terminate inflammatory cascades.
- **Neurological and Cognitive Support**: DHA constitutes approximately 30–40% of total fatty acids in neuronal membrane phospholipids and is essential for synaptic plasticity, neurotransmitter receptor function, and myelination; observational evidence and RCTs suggest higher DHA intake correlates with slower cognitive decline and reduced risk of dementia in older adults.
- **Triglyceride Lowering**: At therapeutic doses of 3–4 g EPA+DHA per day, fish oil reduces fasting serum triglycerides by an average of 25–30% in hypertriglyceridemic patients, an effect confirmed across dozens of RCTs and the basis for FDA-approved prescription formulations including icosapentaenoic acid ethyl ester and omega-3 acid ethyl esters.
- **Platelet Aggregation and Thrombosis Inhibition**: EPA competes with arachidonic acid for cyclooxygenase-1, reducing synthesis of thromboxane A2 (a potent platelet aggregator and vasoconstrictor) while increasing production of thromboxane A3 (biologically weak), thereby modestly prolonging bleeding time and reducing thrombotic risk.
- **Mood and Depression Support**: Multiple RCTs and meta-analyses indicate that EPA-predominant formulations (EPA:DHA ratio ≥2:1) at doses of 1–2 g EPA/day produce clinically meaningful reductions in depressive symptoms, likely through modulation of neuroinflammatory pathways, serotonin receptor signaling, and hypothalamic-pituitary-adrenal axis activity.
- **Eye Health and Retinal Function**: DHA is the dominant structural fatty acid in photoreceptor outer segment membranes, comprising up to 50% of total fatty acids in rod photoreceptors; adequate DHA intake supports visual acuity development in infants and is associated with reduced progression of age-related macular degeneration in observational studies and select supplementation trials.

How It Works

EPA and DHA incorporate into the sn-2 position of cell membrane phospholipids, altering membrane fluidity, lipid raft organization, and the function of embedded receptors and ion channels, including G-protein-coupled receptors and voltage-gated ion channels relevant to cardiac electrophysiology. Both fatty acids activate peroxisome proliferator-activated receptors (PPARα and PPARγ), nuclear receptors that upregulate genes governing fatty acid oxidation and downregulate hepatic lipogenesis, explaining the triglyceride-lowering effect at the transcriptional level. EPA and DHA are enzymatically converted by cyclooxygenase-2 and 5-lipoxygenase into specialized pro-resolving mediators — resolvins (E-series from EPA, D-series from DHA), protectins, and maresins — that bind specific GPCRs (e.g., FPR2/ALX, ChemR23, GPR32) on leukocytes and macrophages to actively promote resolution of inflammation without immunosuppression. Additionally, DHA-derived docosanoids modulate NF-κB signaling by stabilizing IκBα, thereby reducing transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, while EPA reduces leukotriene B4 synthesis by competing with arachidonic acid at 5-lipoxygenase.

Scientific Research

Omega-3 PUFA supplementation is among the most extensively studied nutritional interventions in cardiovascular medicine, with evidence from hundreds of RCTs, multiple systematic reviews, and meta-analyses encompassing over 150,000 participants. The REDUCE-IT trial (n=8,179; NEJM 2018) demonstrated that 4 g/day of icosapentaenoic acid ethyl ester (EPA-only) reduced the primary composite endpoint of major adverse cardiovascular events by 25% (HR 0.75; 95% CI 0.68–0.83) in statin-treated patients with elevated triglycerides, representing one of the largest cardiovascular benefit signals seen in a lipid-modifying trial. In contrast, the STRENGTH trial (n=13,078) using a high-dose EPA+DHA carboxylic acid formulation found no significant reduction in cardiovascular events versus a corn oil comparator, raising questions about whether the REDUCE-IT benefit is EPA-specific or partially attributable to the mineral oil placebo used in that trial. Meta-analyses across broad omega-3 RCT populations consistently confirm triglyceride reduction (effect size approximately −0.45 mmol/L at 1–4 g/day) and modest but statistically significant reductions in myocardial infarction and cardiovascular death, with neurological, mood, and anti-inflammatory benefits supported by smaller but growing bodies of RCT evidence.

Clinical Summary

The most pivotal clinical finding for omega-3 PUFAs is the EPA-specific cardiovascular protection demonstrated in REDUCE-IT (2018), where statin-background patients with hypertriglyceridemia receiving 4 g/day icosapentaenoic acid ethyl ester showed a number-needed-to-treat of approximately 21 to prevent one major cardiovascular event over 4.9 years. Triglyceride reduction is the most pharmacologically consistent outcome, with a 2012 Cochrane-style meta-analysis of 47 RCTs confirming a mean triglyceride reduction of 14.9% at approximately 3.35 g/day EPA+DHA. For depression, a 2019 meta-analysis of 26 RCTs (n=2,160) found EPA-predominant formulations produced a standardized mean difference of −0.61 (95% CI −0.91 to −0.31) compared to placebo in diagnosable depressive disorders. Confidence in cardiovascular and triglyceride outcomes is high based on consistent replication; evidence for cognitive, anti-inflammatory, and mood benefits is moderate and dependent on dose, formulation, and population baseline omega-3 status.

Nutritional Profile

Marine fish oils provide EPA at 142–176 mg/g and DHA at 40–94 mg/g in commercial concentrated forms, alongside saturated fatty acids (primarily palmitic acid C16:0) at 324–350 mg/g and a favorable n-3/n-6 ratio of approximately 6.4:1. Natural fish tissue contains more modest concentrations: EPA 9–14 mg/g and DHA 9–25 mg/g depending on species, season, and feed source, with cold-water pelagic species (sardine, anchovy, herring, mackerel) being the richest sources. Fish oils are also notable for their content of fat-soluble vitamins, particularly vitamin D3 (cholecalciferol) at up to 2,000–3,000 IU per 100 mL in cod liver oil, and vitamin A (retinol), though these are largely removed in highly refined fish oil concentrates. Krill oil formulations additionally contain astaxanthin (0.5–2 mg/g), a marine keto-carotenoid with antioxidant activity that may protect EPA and DHA from lipid peroxidation during storage and in vivo. Bioavailability varies significantly by molecular form: phospholipid-bound EPA/DHA (krill oil) provides approximately 10–15% greater systemic absorption; re-esterified triglyceride forms show approximately 124% relative bioavailability compared to ethyl ester forms; and all lipid forms exhibit substantially enhanced absorption (up to 50% increase in AUC) when consumed with a fat-containing meal.

Preparation & Dosage

- **Standard Fish Oil Softgels (TG form)**: 1,000 mg softgels typically providing 180 mg EPA + 120 mg DHA; 2–3 capsules daily for general health maintenance; take with meals to improve absorption by up to 50%.
- **Concentrated Fish Oil (Ethyl Ester form)**: 1,000–1,200 mg EPA+DHA per capsule; 2–4 capsules daily for cardiovascular or triglyceride-lowering purposes; ethyl ester form has slightly lower bioavailability than re-esterified TG unless consumed with a high-fat meal.
- **Re-Esterified Triglyceride (rTG) Concentrates**: 600–900 mg EPA+DHA per capsule with superior bioavailability (~124% relative to ethyl esters); preferred pharmaceutical-grade form for clinical applications; dose 2–4 g EPA+DHA per day for hypertriglyceridemia.
- **Prescription Formulations (Vascepa/Lovaza)**: Icosapentaenoic acid ethyl ester (EPA-only, 4 g/day in 4 capsules) or omega-3 acid ethyl esters (3.6 g EPA+DHA/day in 4 capsules); FDA-approved for triglyceride reduction ≥500 mg/dL.
- **Krill Oil Phospholipid Form**: 300–500 mg EPA+DHA per capsule in phosphatidylcholine-bound form; lower absolute dose required due to enhanced bioavailability (~10–15% greater AUC vs. standard fish oil TG); also provides astaxanthin 0.5–2 mg.
- **Algal Oil (Vegan DHA/EPA)**: 291–378 mg EPA+DHA per gram of oil; 1–2 capsules daily; DHA-dominant (179–259 mg/g DHA); preferred for vegetarians, pregnant women, and those avoiding marine allergens.
- **Clinical Dosing Thresholds**: Anti-inflammatory and mood effects: ≥1 g EPA+DHA/day; triglyceride lowering: 2–4 g EPA+DHA/day; maximum cardioprotective benefit in high-risk patients: 4 g/day EPA (icosapentaenoic acid ethyl ester as per REDUCE-IT protocol).

Synergy & Pairings

EPA and DHA exhibit synergistic anti-inflammatory and cardioprotective effects when combined with astaxanthin (as naturally co-occurring in krill oil), because astaxanthin's potent singlet oxygen quenching activity (estimated 6,000-fold greater than vitamin C) protects highly unsaturated omega-3 fatty acids from in vivo lipid peroxidation and extends their bioactive half-life in circulation. Co-administration of omega-3 PUFAs with magnesium has demonstrated additive antihypertensive and anti-arrhythmic effects in small clinical studies, as both agents independently modulate calcium channel activity and vascular smooth muscle tone. The combination of EPA/DHA with coenzyme Q10 is mechanistically rational for patients on statin therapy, where statin-induced CoQ10 depletion may attenuate mitochondrial function and contribute to myopathy, while omega-3s provide complementary lipid-modifying and anti-inflammatory benefits not achieved by statins alone.

Safety & Interactions

At typical supplemental doses of 1–3 g EPA+DHA/day, fish oil is well tolerated; the most common adverse effects are gastrointestinal — fishy aftertaste, burping, nausea, and loose stools — which are reduced by taking enteric-coated capsules with meals, storing capsules in the freezer, or switching to re-esterified triglyceride forms. At therapeutic doses of 3–4 g/day, clinically meaningful antiplatelet effects occur, and fish oil should be used with caution in combination with anticoagulants (warfarin, direct oral anticoagulants) and antiplatelet drugs (clopidogrel, aspirin), as combined use may increase bleeding risk, though RCT data suggest this risk is modest and manageable with monitoring; the European Society of Cardiology and the American Heart Association note that omega-3 supplementation up to 4 g/day can be used safely alongside anticoagulation with appropriate INR monitoring. High doses (>3 g/day) may modestly increase LDL-cholesterol in some patients with mixed dyslipidemia, and fish oil derived from liver sources (e.g., cod liver oil) contains vitamin A and D that can cause toxicity with prolonged high-dose use; body oil concentrates from commercial fish tissue rather than liver are preferred for high-dose supplementation. Fish oil is considered safe during pregnancy and lactation at recommended doses (200–300 mg DHA/day for pregnant and nursing women per EFSA guidance), and DHA supplementation during pregnancy supports fetal brain and retinal development; fish oil supplements that are third-party tested for heavy metals (mercury, lead, cadmium) and PCBs are preferred, as refining processes vary in their removal efficiency of environmental contaminants.